PRIMARY HYPEROXALURIA TYPE 1
Clinical trials for PRIMARY HYPEROXALURIA TYPE 1 explained in plain language.
Never miss a new study
Get alerted when new PRIMARY HYPEROXALURIA TYPE 1 trials appear
Sign up with your email to follow new studies for PRIMARY HYPEROXALURIA TYPE 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug, YOLT-203, in 36 children and adults with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The goal is to see if a single dose can safely lower oxalate levels in urine and blood…
Matched conditions: PRIMARY HYPEROXALURIA TYPE 1
Phase: PHASE2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare kidney disease: drug targets oxalate buildup in severe cases
Disease control Recruiting nowThis phase 2 study tests a drug called nedosiran (DCR-PHXC) in 28 people with primary hyperoxaluria type 1 (PH1) who have severe kidney impairment, with or without dialysis. The goal is to see if the drug safely lowers plasma oxalate levels, which can cause kidney stones and dama…
Matched conditions: PRIMARY HYPEROXALURIA TYPE 1
Phase: PHASE2 • Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC